Discover and read the best of Twitter Threads about #EASD2021
Most recents (8)
Welcome to our final Goggledocs tweetorial from this #EASD2021 takeover!
Over the last few days we have discussed all things cardio-reno-metabolic including SGLT2s, GLP1s, dual agonists, triple agonists….but not mentioned much about type 1 diabetes…
Over the last few days we have discussed all things cardio-reno-metabolic including SGLT2s, GLP1s, dual agonists, triple agonists….but not mentioned much about type 1 diabetes…
So today we are going to end on a cardiometabolic focused look at Type 1 Diabetes with data from #EASD2021 interwoven in... stay tuned!
One of the key sessions and guidance from @EASDnews #EASD2021 was the formalized joint ADA-EASD consesnsus report for management of type 1 diabetes… care.diabetesjournals.org/content/early/…
The @GoggleDocs takeover of @cardiomet_CE continues!
We are 4 UK 🇬🇧 based doctors working across primary & secondary healthcare
Our interests are "what's new, and meaningful, in cardiorenal metabolic medicine"
Check out our YouTube channel youtube.com/c/GoggleDocs
We are 4 UK 🇬🇧 based doctors working across primary & secondary healthcare
Our interests are "what's new, and meaningful, in cardiorenal metabolic medicine"
Check out our YouTube channel youtube.com/c/GoggleDocs
Yesterday we had key messages from ReTune & diabetes remission & TriMASTER exploring “what next after metformin?”
Today @goggledocs will take you through some SGLT2 inhibitor highlights from #EASD2021 - the gift that keeps on giving!
Today @goggledocs will take you through some SGLT2 inhibitor highlights from #EASD2021 - the gift that keeps on giving!
Let’s start with some history!
SGLT2 inhibitors were originally developed from natural compounds found in what?
SGLT2 inhibitors were originally developed from natural compounds found in what?
Yes it's the @GoggleDocs as we continue our #takeover of the @cardiomet_CE account.
Reporting some of the things that interested us in the recent #EASD2021
Please check out our previous mini-tweetorials.
@EASDnews @EASDelearning @ADA_DiabetesPro
Reporting some of the things that interested us in the recent #EASD2021
Please check out our previous mini-tweetorials.
@EASDnews @EASDelearning @ADA_DiabetesPro
Thus far we have covered...
▶️ Latest data on tirzepatide (GIP/GLP-1 dual agonist)✅
▶️ "Triple G" - a new GIP/GLP-1/Glucagon agonist✅
▶️ Remission in non-obese #type2diabetes ✅
Next up is "what's next after metformin?" - what the GRADE & TriMaster Studies add
▶️ Latest data on tirzepatide (GIP/GLP-1 dual agonist)✅
▶️ "Triple G" - a new GIP/GLP-1/Glucagon agonist✅
▶️ Remission in non-obese #type2diabetes ✅
Next up is "what's next after metformin?" - what the GRADE & TriMaster Studies add
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
📍Presented an update at the #EASD2021 , although little changed from the #ADA2021 presentation.
Please check out one of our own @GoggleDocs posts at the time
📍Presented an update at the #EASD2021 , although little changed from the #ADA2021 presentation.
Please check out one of our own @GoggleDocs posts at the time
Time for a shit in gear as the @GoggleDocs continue their £takeover of the @cardiomet_CE account.
From treatments that are still in the development stage now back to basics.
In this mini-thread today we are going to cover a couple of sessions from #EASD2021 that caught our 👁️
From treatments that are still in the development stage now back to basics.
In this mini-thread today we are going to cover a couple of sessions from #EASD2021 that caught our 👁️
First up led by Prof. Roy Taylor of @UniofNewcastle in collaboration with the @UniofOxford Diabetes Trial Unit.
You may remember Prof. Taylor from the seminal DiRECT Study 👉directclinicaltrial.org.uk
Today I will be going through some of the preliminary data from the ReTune Study
You may remember Prof. Taylor from the seminal DiRECT Study 👉directclinicaltrial.org.uk
Today I will be going through some of the preliminary data from the ReTune Study
📍Twin Cycle Hypothesis (R. Tayor 2008) of #type2diabetes
📍Once an individual' subcutaneous fat reserves are full
▶️ Fat is stored in the liver
▶️ Liver derived VLDL in turn, among other things, ⤴️ pancreatic fat
▶️⤴️pancreatic fat leads onto ⤵️ insulin secretion to food
📍Once an individual' subcutaneous fat reserves are full
▶️ Fat is stored in the liver
▶️ Liver derived VLDL in turn, among other things, ⤴️ pancreatic fat
▶️⤴️pancreatic fat leads onto ⤵️ insulin secretion to food
It's Monday and time for us @GoggleDocs to #takeover the @cardiomet_CE account for the next few days.
It's time to revisit the recent #EASD2021 conference.
Highlights in what's new in
#T1D
#type2diabetes
#NAFLD
#CKD
#HeartFailure
It's time to revisit the recent #EASD2021 conference.
Highlights in what's new in
#T1D
#type2diabetes
#NAFLD
#CKD
#HeartFailure
Just to remind you guys
The @GoggleDocs are a bunch of 🇬🇧 docs/🤓 who are fascinated about the cardio-metabolic conditions we are increasingly managing.
Please check out our @YouTube channel
youtube.com/channel/UC8Tzu…
The @GoggleDocs are a bunch of 🇬🇧 docs/🤓 who are fascinated about the cardio-metabolic conditions we are increasingly managing.
Please check out our @YouTube channel
youtube.com/channel/UC8Tzu…
This accredited educational program is intended for healthcare providers only, and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk. Follow this thread for a link to credit. CE/#CME credit for #physicians, #nurses, #pharmacists in US, Canada, GB, EU.
Up next: the 36th Camillo Golgi lecture! #EASD2021
This year’s speaker is… #EASD2021
We have to interrupt this vicious circle #EASD2021
EASD President Professor Stefano Del Prato @SDelprato virtually welcomes everyone to #EASD2021 - he is confident that this year will be another successful meeting, following the more than 20,000 delegates last year!
Globally, EASD is aiming to reach and connect as many people as possible. Last year we had delegates from Brazil and Mexico joining the meeting! #EASD2021
Amazing stats for this year’s meeting! #EASD2021
It’s #EASD2021 week 🥳🥳🥳
We can’t wait to share our new #eLearning modules and other initiatives with you! Once again, this year’s conference is virtual – and there are some new ‘live’ twists to tempt you in, too. #MedTwitter #Diabetes
Read more: easd-elearning.org/conference-cou…
We can’t wait to share our new #eLearning modules and other initiatives with you! Once again, this year’s conference is virtual – and there are some new ‘live’ twists to tempt you in, too. #MedTwitter #Diabetes
Read more: easd-elearning.org/conference-cou…
Firstly, make sure you watch EASD President Stefano Del Prato’s opening address tomorrow (Tues 28 Sept at 10am CET). Stefano will be announcing some exciting news about the #eLearning platform and what we will be able to offer our users in the future! #EASD2021 #Diabetes
Starting on Weds 29 Sept, we’re launching new #eLearning modules, featuring live Q&A sessions with the course authors.
At 12pm CET, ‘Fear of Hypoglycaemia’ with Professor Frank Snoek
At 2pm CET, ‘NAFLD - Prevention and Treatment’ with Professor Michael Roden
#EASD2021
At 12pm CET, ‘Fear of Hypoglycaemia’ with Professor Frank Snoek
At 2pm CET, ‘NAFLD - Prevention and Treatment’ with Professor Michael Roden
#EASD2021
